Schedule 13G ownership disclosure
Celldex Therapeutics Inc
Common Stock · CUSIP: 15117B202
Event date: 2024-12-31
- Filing-level shares
- 5,480,670
- Percent of class
- 8.3%
- BlackRock, Inc.
Shares: 5,480,670 · Class: 8.3%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0002012383-25-001193
- Form type
- SCHEDULE 13G/A
- Filer
- BlackRock, Inc.
- CIK
- CIK 2012383
- Filed
- Feb 05, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership